<DOC>
	<DOC>NCT02204046</DOC>
	<brief_summary>The primary objectives of this study were to assess the safety and tolerability of intravenously (i.v.) administered 186Rhenium (186Re)-labelled bivatuzumab and to investigate the biodistribution and pharmacokinetics of 186Re-labelled bivatuzumab in patients with adenocarcinoma of the breast</brief_summary>
	<brief_title>Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients must have histological or cytological confirmation of a primary adenocarcinoma of the breast Patients destined for tumour extirpation or mastectomy Patients over 18 years of age Patients younger than 80 years of age Patients who had given 'written informed consent' Patients with a life expectancy of at least 3 months Patients with a good performance status: Karnofsky &gt; 60 Lifethreatening infection, allergic diathesis, organ failure (bilirubin &gt; 30µmol/l and/or creatinine &gt; 150 µmol/l) or evidence of a recent myocardial infarction on ECG or unstable angina pectoris Premenopausal women (last menstruation &lt;= 1 year prior to study start) Not surgically sterile (hysterectomy, tubal ligation) and Not practicing acceptable means of birth control, (or not planned to be continued throughout the study). Acceptable methods of birth control include oral, implantable or injectable contraceptives Women with a positive serum pregnancy test at baseline White blood cell count &lt; 3000/mm³, granulocyte count &lt; 1500/mm³ or platelet count &lt; 100000/mm³. Details of prior chemotherapy or radiotherapy had to be known Hematological disorders, congestive heart failure, bronchial asthma, alimentary or contact allergy, severe atopy or allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>